Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Helsinn Group

www.helsinn.com

Latest From Helsinn Group

New CEO of Renamed Spin-Out Fortovia Therapeutics Will Be ‘Solely US-Focused’

Newly installed Fortovia Therapeutics CEO Peter Melnyk tells Scrip his arrival and the company’s name change from Midatech Pharma US signals a strategic revamp for the privately held spin-out.

Commercial Companies

Oncology Dominates As China Approves Record 48 New Drugs In 2018

Despite multiple adverse factors including a leadership shakeup and the departure of its top regulator, the China FDA seemed determined to refresh itself after a name change and to speed up new drugs to market.

China Pink Sheet Perspectives

AmerisourceBergen Settlement On Injectable Drug Repackaging Includes Forfeiture Of Exec Pay

Corporate integrity agreement attached to second DOJ settlement over repackaging of injectable cancer drugs would require recoupment of exec performance pay following misconduct.

Legal Issues Cancer

Flurry Of Marketing Collaborations Set India Deal Street Abuzz

In-licensing and co-marketing/co-promotion deals are on the up in India, as local and foreign companies tango together to reach more patients and expand their business in the country's competitive market. Lupin-Boehringer, Dr Reddy’s-UCB and Glenmark-Helsinn are among the recent companies doing deals in the area.

India Commercial
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Helsinn Healthcare SA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Helsinn Group
  • Senior Management
  • Riccardo Braglia, CEO
    Konrad Wilson, CFO
    Sergio Cantoreggi, CSO
    Andrea Meoli, Chief Commercial Officer
    Giorgio Calderari, COO
  • Contact Info
  • Helsinn Group
    Phone: (41) 91 985 21 21
    Via Pian Scairolo 9
    Pazzallo -Lugano, 6912
    Switzerland
UsernamePublicRestriction

Register